4Filing Date: Jun 5, 2026

Guardant Health (GH)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001666236-26-000018
Total Value$1.23M
Trades1
Insiders1

Transaction Details

Krognes Steve E.
Director·Direct
Sell · Dispose
Common Stock
Shares-9.29K
Price$132.51
Total Value$1.23M
Shares Owned After10.22K
Transaction DateJun 4, 2026
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Post-Transaction Holdings

Krognes Steve E. · Director
SecuritySharesChange
Common Stock10.22K-9.29K (-47.62%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-06-04 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Guardant Health, Inc. (GH) CIK: 0001576280 --- Reporting Owner --- Name: Krognes Steve E. CIK: 0001666236 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-06-04 | Code: S (Open market sale) Shares: -9,294 | Price: $132.51 Total Value: $1,231,521.92 Shares Owned After: 10,222 | Ownership: D (Direct) Footnotes: [F1] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Footnotes (Complete Index) --- F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Signature --- /s/ /s/ John Saia, as attorney-in-fact for Steve Krognes (2026-06-05)

keid analysis is for reference only and does not constitute investment advice.